Victor Tochukwu Njoku

Mr. Victor Tochukwu Njoku

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Proteomes
Verified
Journal Article
Open access
PDF file
ANAnca-Narcisa Neagu
Anca-Narcisa Neagu
PBPathea S. Bruno
Pathea S. Bruno
CJClaudiu Laurentiu Josan
Claudiu Laurentiu Josan
NWNatalie Darcy Waterman
Natalie Darcy Waterman
HMHailey Morrissiey
Hailey Morrissiey
Costel DarieCostel Darie
Costel Darie
Cancer detection has made significant progress, moving from conventional methods to innovative, non-invasive or minimally invasive approaches aimed at improving early diagnosis, precision, and treatment outcomes. This review examines current and emerging diagnostic technologies, including liquid biopsy (LB), molecular biomarkers, and artificial intelligence (AI). LB analyzes biomarkers in bodily fluids, showing promise in detecting tumors at molecular levels, monitoring cancer progression, and predicting treatment responses. The assignment of specific proteoforms, often linked to tumor subtype, stage, and therapy resistance, adds another layer of diagnostic precision, offering valuable insights for personalized oncology. However, the clinical application of LB faces challenges related to sensitivity, specificity, tumor heterogeneity, and a lack of standardized protocols. Relatively high costs, complex result interpretation, and privacy concerns also hinder its widespread adoption in clinical practice. Despite these challenges, advancements in AI, nanotechnology, and multi-omics strategies offer opportunities to enhance cancer diagnostic accuracy. Future developments, including wearable biosensors and lab-on-a-chip technologies, could lead to personalized, real-time cancer detection with improved patient outcomes, potentially redefining cancer care and fostering a more proactive, patient-centered healthcare approach.

1 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
LSLogan Seymour
Logan Seymour
NNNiyogushima Nuru
Niyogushima Nuru
KJKaya Johnson
Kaya Johnson
JGJennifer Michel Villalpando Gutierrez
Jennifer Michel Villalpando Gutierrez
Victor Tochukwu NjokuVictor Tochukwu Njoku
Victor Tochukwu Njoku
ANAnca-Narcisa Neagu
Anca-Narcisa Neagu
BC is the most commonly diagnosed cancer and the second leading cause of cancer death among women worldwide. Cellular stress is a condition that leads to disrupted homeostasis by extrinsic and intrinsic factors. Among other stressors, hypoxia is a driving force for breast cancer (BC) progression and a general hallmark of solid tumors. Thus, intratumoral hypoxia is an important determinant of invasion, metastasis, treatment failure, prognosis, and patient mortality. Acquisition of the epithelial–mesenchymal transition (EMT) phenotype is also a consequence of tumor hypoxia. The cellular response to hypoxia is mainly regulated by the hypoxia signaling pathway, governed by hypoxia-inducible factors (HIFs), mainly HIF1α. HIFs are a family of transcription factors (TFs), which induce the expression of target genes involved in cell survival and proliferation, metabolic reprogramming, angiogenesis, resisting apoptosis, invasion, and metastasis. HIF1α cooperates with a large number of other TFs. In this review, we focused on the crosstalk and cooperation between HIF1α and other TFs involved in the cellular response to hypoxia in BC. We identified a cluster of TFs, proposed as the HIF1α-TF interactome, that orchestrates the transcription of target genes involved in hypoxia, due to their post-translational modifications (PTMs), including phosphorylation/dephosphorylation, ubiquitination/deubiquitination, SUMOylation, hydroxylation, acetylation, S-nitrosylation, and palmitoylation. PTMs of these HIF1α-related TFs drive their stability and activity, degradation and turnover, and the bidirectional translocation between the cytoplasm or plasma membrane and nucleus of BC cells, as well as the transcription/activation of proteins encoded by oncogenes or inactivation of tumor suppressor target genes. Consequently, PTMs of TFs in the HIF1α interactome are crucial regulatory mechanisms that drive the cellular response to oxygen deprivation in BC cells.

1 January 2026
Verified
Book Chapter
Closed access
Victor Tochukwu NjokuVictor Tochukwu Njoku
Victor Tochukwu Njoku
AMAntea Metaliaj
Antea Metaliaj
CDCostel C. Darie
Costel C. Darie
TBTimothy Blenkinsop
Timothy Blenkinsop
ARAurelian Radu
Aurelian Radu

1 January 2026
Verified
Book Chapter
Closed access
PDF file
AAAneeta Arshad
Aneeta Arshad
PBPathea S. Bruno
Pathea S. Bruno
Victor Tochukwu NjokuVictor Tochukwu Njoku
Victor Tochukwu Njoku
TJTaniya M. Jayaweera
Taniya M. Jayaweera
KWKelly L. Wormwood
Kelly L. Wormwood
RARoshanak Aslebagh
Roshanak Aslebagh

1 January 2026
Verified
Book Chapter
Closed access
PDF file
PBPathea S. Bruno
Pathea S. Bruno
TJTaniya M. Jayaweera
Taniya M. Jayaweera
AAAneeta Arshad
Aneeta Arshad
Victor Tochukwu NjokuVictor Tochukwu Njoku
Victor Tochukwu Njoku
SAStephanie Andreescu
Stephanie Andreescu
Costel DarieCostel Darie
Costel Darie

1 January 2026
Verified
Book Chapter
Closed access
PDF file
Victor Tochukwu NjokuVictor Tochukwu Njoku
Victor Tochukwu Njoku
BPBenjamin Priest
Benjamin Priest
Costel DarieCostel Darie
Costel Darie